May 05, 2022 4:01 pm EDT Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
Apr 29, 2022 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 28, 2022 4:01 pm EDT Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
Apr 22, 2022 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 08, 2022 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 05, 2022 4:01 pm EDT Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer
Apr 04, 2022 4:01 pm EDT Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm
Mar 04, 2022 4:01 pm EST Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Mar 02, 2022 8:00 am EST Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 42nd Annual Virtual Healthcare Conference